Former Genmab execs launch new biotech company
Behind the scenes, four former Genmab executives have joined forces in a new biotech company which also focuses on antibody-based immunotherapy. The company already has two drug candidates in phase 2 for the treatment of a rare form of children’s cancer, as well as a baron investor.
BY LONNI LYNGE
Four former executives from the Danish biotech company Genmab have quietly combined forces in a new biotech company which, just like Genmab, focuses on antibody-based immunotherapy. CEO of Y-mAbs Therapeautics Inc. is Claus Juan Møller-San Pedro, who helped found Genmab and served as COO until 2008. He also founded Azanta where he was CEO until last April. Now, he hopes to do the same at Y-mAbs as he did at Genmab.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Genmab's sclerosis hope takes big step forward
For abonnenter
Pharmaceutical industry tops the productivity list
For abonnenter
